Fidson Healthcare Plc engages in the manufacture and distribution of pharmaceutical products in Nigeria. The company offers pharmaceutical products in various therapeutic areas, such as anti-infective, anti-arthritis, endocrinology, gastro-intestine, anti-retroviral, anti-malaria, cardiovascular, anti-depressant, pain relievers, haematinics, cough expectorants, and consumer goods. Its principal products include Biosulin-N, which is an anti-diabetic insulin; Gascol for heartburn, indigestion, dyspepsia, flatulence, and other acid-related disorders; Asomex 2.5 for acute uncomplicated UTI, complicated UTI, enteric fever, bone and joint infections, and adnexitis and prostatitis2; and Cutenox for the prevention of thrombosis in hospitalized medical and surgical patients. The company also offers Flutex for patients with depressive disorder, obsessive compulsive disorders, and bulima nervosa; Ciprotab 500, a second generation fluoroquinolone antibiotic for the treatment of various infections; ZETGEL to relieve pain in osteoarthrtis; and Astyfer Blood Builder for use in pregnancy, lactation, anaemia, haemorrhoids, anal fissures, chronic gastric ulcers, and iron deficiency; and Tuxil-C cough expectorant. In addition, it provides Formula 103, a razor less hair removal for men and women; baby diapers under Cuddles name; and tissue products under Fluffy brand. The company was incorporated in 1995 and is headquartered in Lagos, Nigeria.

Website:	www.fidson.com
Founded in:	1995

Statement of Comprehensive Income as at
31-Mar-2018